Abstract
Prostate cancer is the second most commonly diagnosed cancer and the sixth leading cause of cancer death among men worldwide, with an estimated 1 276 000 new cancer cases and 359 000 deaths in 2018[1]. The median age at diagnosis is 66 year, and 69% of deaths occur in men aged 75 yr[2]. As the morbidity and mortality rates rise sharply with age, the burden of prostate cancer will increase with the exponential aging of the population. The pathological type of prostate cancer is mainly adenocarcinoma (98.1%), and other types are relatively rare. Other pathological types of prostate cancer include iprostate duct (endometrioid) ademocarcinoma, small cell carcinoma, smucinous adenocarcinoma, signet ring cell carcinoma, transitional cell carcinoma, Sarcomatoid carcinoma, squamous cell carcinoma, lymphoepithelioid carcinoma, adenoid cystic carcinoma, etc. Rhabdomyosarcoma (RMS) is a soft tissue sarcoma that histologically resembles embryonic skeletal muscle. It can occur anywhere in the body, including tissues devoid of skeletal muscles. The cell of origin of RMS remains unknown, however, recent evidence suggests that RMS can originate from aberrant development of non-myogenic cells [3]. Rhabdomyosarcoma is a common malignant tumor in children. In fact, it accounts for more than 50% of all soft tissue sarcomas in children [4]. However, rhabdomyosarcoma is a rare adult malignant tumor, and it accounts for only 3% of all soft tissue sarcomas [5]. Rhabdomyosarcoma is very rare in prostate tumors.